Want to see CYRX full AI Analyst Report?
Revenue by Segment
Details revenue from different customer or product segments (for example clinical trials, commercial biopharma, or logistics solutions), showing where demand is concentrated and how exposed the company is to particular markets or customers.
Excluding a one‑time Q4 2024 spike (and matching large elimination), Life Sciences Services and Products show steady, organic double‑digit growth with Services gaining faster—aligning with management’s strong Q1, raised 2026 guide, and record clinical trial base. That underlying growth is driving the move toward positive adjusted EBITDA, but near‑term upside depends on H2 2026 execution: watch for IntegraCell and new facility ramps, clinical→commercial conversions, and whether product‑mix volatility eases to sustain margin improvement.
CYRX Revenue by Segment
| Date | Eliminations | Life Sciences Services | Life Sciences Products |
|---|---|---|---|
| Jun 30, 2026 | -$1.25M | $28.68M | $21.54M |
| Mar 31, 2026 | -$972.00K | $27.91M | $20.86M |
| Dec 31, 2025 | -$467.00K | $26.94M | $18.98M |
| Sep 30, 2025 | -$316.00K | $25.73M | $18.82M |
| Jun 30, 2025 | -$561.00K | $26.02M | $19.99M |
| Mar 31, 2025 | -$395.00K | $23.46M | $17.98M |
| Dec 31, 2024 | -$6.36M | $100.45M | $18.98M |
| Sep 30, 2024 | -$262.00K | $21.51M | $17.07M |
| Jun 30, 2024 | -$373.00K | $21.75M | $18.33M |
| Mar 31, 2024 | -$257.00K | $19.96M | $17.59M |
